8-K: Fortress Biotech's ZYCUBO Approved for Menkes Disease

Fortress Biotech and its subsidiary Cyprium Therapeutics announced FDA approval for ZYCUBO, the first and only treatment for Menkes disease, securing a Rare Pediatric Disease Priority Review Voucher.

Summary

• The U.S. Food and Drug Administration (FDA) approved ZYCUBO (copper histidinate) for the treatment of Menkes disease in pediatric patients on January 13, 2026.
• ZYCUBO is the first and only FDA-approved treatment for Menkes disease in the United States.
• A Rare Pediatric Disease Priority Review Voucher (PRV) was issued in connection with the FDA approval and will be transferred to Cyprium Therapeutics, Inc., a majority-owned subsidiary of Fortress Biotech.
• Cyprium is eligible to receive tiered royalties on net sales of ZYCUBO and up to $129 million in aggregate development and sales milestones from Sentynl Therapeutics, Inc.
• Clinical efficacy results demonstrated a nearly 80% reduction in the risk of death for Menkes disease subjects who received early treatment with ZYCUBO, compared to an untreated contemporaneous external control cohort.
• Median overall survival (OS) was 177.1 months for the ZYCUBO early treatment cohort compared to 17.6 months for the external control cohort.
• ZYCUBO has received Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug Designation from the FDA, and Orphan Designation by the European Medicines Agency.
• Fortress Biotech highlights this as its third FDA approval in the last 15 months, alongside Emrosi and UNLOXCYT, and the recent sale of Checkpoint Therapeutics for approximately $28 million upfront plus potential contingent value right (CVR) payment and ongoing royalties.

Sentiment

Score: 9

Explanation: The FDA approval of the first and only treatment for a rare, fatal pediatric disease, coupled with a valuable PRV and significant potential milestone payments, represents a major positive catalyst for Fortress Biotech and its subsidiary. The strong clinical efficacy data further reinforces the positive outlook, despite the inherent risks of drug development and commercialization.

Positives

• FDA approval of ZYCUBO marks the first and only approved treatment for Menkes disease in the U.S., addressing a critical unmet medical need.
• Receipt of a valuable Rare Pediatric Disease Priority Review Voucher (PRV), which can be sold for significant non-dilutive capital.
• Cyprium is eligible for tiered royalties on ZYCUBO net sales and up to $129 million in aggregate development and sales milestones from Sentynl Therapeutics.
• Strong clinical efficacy data showing a nearly 80% reduction in the risk of death and significantly extended median overall survival (177.1 months vs. 17.6 months for untreated controls).
• ZYCUBO holds multiple valuable designations: Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug.
• This is Fortress Biotech's third FDA approval in 15 months, demonstrating successful execution of its business model and pipeline development.
• Recent sale of Checkpoint Therapeutics for approximately $28 million upfront, with potential for additional CVR payment and ongoing royalties, further strengthening Fortress Biotech's financial position.

Negatives

• ZYCUBO has potential adverse reactions, with the most common (>7%) including pneumonia (30%), viral infection (27%), respiratory failure (23%), seizure (23%), and bacterial infection (20%).
• Warnings and precautions include risks of copper accumulation and toxicity, renal dysfunction, liver dysfunction, and hematological abnormalities, requiring careful patient monitoring.
• There is a relatively small universe of potential buyers for a PRV, and there is a possibility that it may not be sold on favorable economic terms or within a desired timeframe.

Risks

• Uncertainty regarding the ability to find a buyer for the Rare Pediatric Disease Priority Review Voucher (PRV) on favorable economic terms or within a desired timeframe.
• Need for substantial additional funds and uncertainties relating to future financings.
• Uncertainty related to the timing and amounts expected to be realized from future milestone, contingent value right, royalty, or similar future revenue streams, if at all.
• Risks associated with identifying, acquiring, closing, and integrating product candidates successfully and on a timely basis.
• Challenges in attracting, integrating, and retaining key personnel.
• Risks inherent in the early stage of products under development and the results of research and development activities.
• Uncertainties relating to preclinical and clinical testing.
• Ability to obtain regulatory approval for products under development.
• Ability to successfully commercialize products or other marketable assets for which regulatory approval is received.
• Ability to secure and maintain third-party manufacturing, marketing, and distribution of products and product candidates.
• Risks related to government regulation, patent and intellectual property matters, and competition.
• Potential for copper accumulation and toxicity, renal dysfunction, liver dysfunction, and hematological abnormalities in patients treated with ZYCUBO, requiring careful monitoring and potential dose adjustments.

Future Outlook

Fortress Biotech anticipates potential achievement of additional upcoming milestones across its extensive pipeline of commercial and clinical-stage assets. The company's business model has demonstrated measurable success and continued execution across the portfolio, with three FDA approvals in the last 15 months and a recent asset sale.

Management Comments

• "The approval of ZYCUBO is a pivotal milestone for our company and patients suffering from Menkes Disease, as it is the first and only FDA-approved treatment for this rare, often fatal, pediatric disease." Lindsay A. Rosenwald, M.D., Fortress Chairman, President and Chief Executive Officer and Cyprium's Chairman.
• "With three FDA approvals received in the last 15 months, for Emrosi, UNLOXCYT (cosibelimab-ipdl), and now ZYCUBO, along with the recent sale of Checkpoint Therapeutics to Sun Pharma for approximately $28 million upfront to Fortress, plus the potential for an additional contingent value right (CVR) payment and ongoing royalties on future sales of UNLOXCYT, we believe that our business model has demonstrated measurable success and continued execution across the portfolio." Lindsay A. Rosenwald, M.D.
• "We look forward to the potential achievement of additional upcoming milestones across our extensive pipeline of commercial and clinical-stage assets." Lindsay A. Rosenwald, M.D.
• "The development and approval of ZYCUBO are the culmination of more than three decades of hard work and dedication by many people, including the team members at Cyprium, Fortress and Sentynl." Lung S. Yam, M.D., Ph.D., Cyprium's President and Chief Executive Officer.
• "We would like to express our gratitude to the Menkes disease patients and their families who participated in the clinical studies and helped advance our understanding of this devastating disease." Lung S. Yam, M.D., Ph.D.

Industry Context

The approval of ZYCUBO represents a significant breakthrough for the rare disease community, particularly for Menkes disease, which previously had no approved treatment in the United States. This addresses a critical unmet medical need for a devastating X-linked recessive pediatric disease characterized by severe neurological symptoms and high mortality in untreated patients. The receipt of a Rare Pediatric Disease Priority Review Voucher underscores the importance of developing therapies for such underserved populations and provides an incentive for pharmaceutical companies to invest in rare disease research.

Comparison to Industry Standards

• ZYCUBO is the first and only FDA-approved treatment for Menkes disease in the United States, establishing a new standard of care for this previously untreatable condition.
• The clinical trial results, demonstrating a nearly 80% reduction in the risk of death and a median overall survival of 177.1 months for early-treated patients compared to 17.6 months for untreated controls, represent a substantial improvement over the natural history of the disease.
• The receipt of a Rare Pediatric Disease Priority Review Voucher (PRV) is a significant achievement, as PRVs are valuable assets often sold for hundreds of millions of dollars, reflecting the high impact of addressing rare pediatric diseases.

Stakeholder Impact

• Patients and Families: Provides the first and only FDA-approved treatment for Menkes disease, offering significantly improved survival and a new standard of care for a previously untreatable, often fatal condition.
• Shareholders (Fortress Biotech): Positive impact due to FDA approval, potential for significant financial returns from PRV sale, royalties, and milestones, validating the company's business model and pipeline.
• Employees (Fortress/Cyprium): Validation of their R&D efforts and dedication, potential for increased job security and growth opportunities.
• Sentynl Therapeutics: Gains a new, approved product for commercialization in the rare disease market.
• Regulatory Authorities (FDA): Successful outcome of the regulatory review process, addressing an unmet medical need.

Next Steps

• Transfer of the Rare Pediatric Disease Priority Review Voucher (PRV) from Sentynl Therapeutics to Cyprium Therapeutics.
• Commercialization of ZYCUBO by Sentynl Therapeutics.
• Potential achievement of additional upcoming milestones across Fortress Biotech's extensive pipeline of commercial and clinical-stage assets.
• Ongoing monitoring of patients for potential adverse reactions and copper accumulation, with dose adjustments as appropriate.
• Continued pre-clinical development of AAV-ATP7A gene therapy for Menkes disease by Cyprium and NICHD.

Key Dates

Recommendation

The FDA approval of ZYCUBO as the first and only treatment for Menkes disease is a transformative event for Fortress Biotech and its subsidiary Cyprium. This approval addresses a critical unmet medical need, supported by highly compelling clinical data showing a nearly 80% reduction in mortality. The accompanying Rare Pediatric Disease Priority Review Voucher (PRV) is a significant, liquid asset that can be sold for substantial non-dilutive capital, historically fetching hundreds of millions of dollars. Furthermore, the potential for up to $129 million in milestones and tiered royalties from Sentynl Therapeutics provides a clear, long-term revenue stream. This success, combined with Fortress Biotech's recent track record of multiple FDA approvals and strategic asset sales, demonstrates strong execution and validates its diversified business model. While risks associated with commercialization and PRV sale exist, the magnitude of this approval and its financial implications suggest a strong positive re-rating potential for the stock.

Keywords

Menkes disease, ZYCUBO, copper histidinate, FDA approval, Rare Pediatric Disease Priority Review Voucher, PRV, Fortress Biotech, Cyprium Therapeutics, Sentynl Therapeutics, Orphan Drug, pediatric patients, biopharmaceutical, rare disease, ATP7A, drug approval, biotech